30 mg retatrutide Buy 30mg UK | High-Dose Reta Retatrutide 30mg | Proven GLP-1

PMID: 36117625

In the ATTAIN-MAINTAIN trial, orforglipron's profile was "consistent with previous orforglipron Phase 3 studies." The most common adverse events were gastrointestinal-related and were generally mild-to-moderate in severity, which is expected for the GLP-1 class

[DOI] [PMC free article] [PubMed] [Google Scholar] 110.Hyde K.M., Blonde G.D., le Roux C.W., Spector A.C

Patients who prepare for the peak side effect period (weeks 6 to 8) by stocking appropriate foods and having anti-nausea remedies ready report 40% less severe symptoms than those who react to symptoms after they appear

We did not conduct meta-analyses for severe hypoglycaemia because events were rare